Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B
Article first published online: 24 SEP 2009
© 2009 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 30, Issue 11-12, pages 1150–1158, December 2009
How to Cite
NGUYEN, M. H., GARCIA, R. T., TRINH, H. N., NGUYEN, H. A., NGUYEN, K. K., NGUYEN, L. H. and LEVITT, B. (2009), Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 30: 1150–1158. doi: 10.1111/j.1365-2036.2009.04151.x
- Issue published online: 2 NOV 2009
- Article first published online: 24 SEP 2009
- Publication data Submitted 20 May 2009 First decision 10 June 2009 Resubmitted 17 September 2009 Accepted 17 September 2009 Epub Accepted Article 24 September 2009
Background One of the most important factors in treatment failure using nucleos(t)ide analogues in chronic hepatitis B is anti-viral resistance. Primary drug resistance refers to amino acid changes in the hepatitis B virus polymerase/reverse transcriptase (rt) that result in reduced susceptibility to anti-viral agents. Pre-existing drug resistance mutations may occur in untreated patients and may affect their treatment outcomes.
Aim To determine the prevalence of hepatitis B DNA polymerase mutations in treatment-naïve patients.
Methods We used a direct PCR sequencing test to detect DNA polymerase mutations in 472 consecutive treatment-naïve patients at two community gastroenterology clinics in Northern California.
Results A majority of patients were Asians (>95%), had either genotype B or C (95%) and had no evidence of cirrhosis or liver cancer (94%). Mean age was 45 ± 13 and mean hepatitis B virus DNA was 5.3 ± 1.8 log10 IU/mL. Most patients did not have any detectable mutations (82.4%). Some (16.7%) had mutations of unknown clinical significance (rtV207M/L/I) and only 4 patients had rtA181A/S, rtA194S or M250I.
Conclusions No rtM204V/I or rtN236T mutations were observed in our study. Less than 1% of our patients had mutations that can be associated with primary resistance to existing anti-viral therapies for hepatitis B virus.